File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Effects of abacavir on the vascular and platelet activities

TitleEffects of abacavir on the vascular and platelet activities
Authors
Issue Date2010
PublisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/yjmcc
Citation
XXth World congress of the International Society for Heart Research, Kyoto, Japan, 13-16 May 2010. In Journal of Molecular and Cellular Cardiology, v. 48 n. 5 Suppl. 1 How to Cite?
AbstractAbacavir is an antiviral nucleoside analogue effectively used to treat HIV infection. However, a study showed that the use of abacavir significantly increased the risks of stroke and myocardial infraction. We sought to investigate the effects of abacavir on vascular and platelet activities so as to understand the underlying mechanisms. Sprague-Dawley rats (330-350 g) were fed with abacavir (16 mg/kg/day, equivalent to the clinical dosage on human) for 28 days by gastric gavage. Isometric tensions of basilar arteries were measured. Aorta mRNA and proteins expressions of various factors related to endothelial function and inflammation were measured by RT-PCR and Western blotting, respectively. To measure the effect of abacavir on platelet activation, the plasma levels of CD40L, a platelet-derived factor which is released upon platelet activation, were measured by ELISA kit. Our results showed that abacavir treatment did not affect the maximum relaxation response of basilar artery. Besides, there were no significant change in the mRNA and protein expression levels of eNOS, COX-1, COX-2 and ICAM-1 in aorta after abacavir treatment. However, a higher plasma level of CD40L was detected in the abacavir-treated group. It is suggested that abacavir does not affect vascular contractility nor induced endothelial inflammation. However, abacavir upregulates the platelet activity, which will theoretically increase the chance of developing thrombosis. This may be a possible explanation for the higher risk of cardiovascular events in patients receiving abacavir treatment.
Descriptionabstract no. P-2-18-6
Persistent Identifierhttp://hdl.handle.net/10722/202385
ISSN
2015 Impact Factor: 4.874
2015 SCImago Journal Rankings: 2.522

 

DC FieldValueLanguage
dc.contributor.authorLi, RWS-
dc.contributor.authorKwan, SYW-
dc.contributor.authorLeung, GPH-
dc.date.accessioned2014-09-18T06:13:16Z-
dc.date.available2014-09-18T06:13:16Z-
dc.date.issued2010-
dc.identifier.citationXXth World congress of the International Society for Heart Research, Kyoto, Japan, 13-16 May 2010. In Journal of Molecular and Cellular Cardiology, v. 48 n. 5 Suppl. 1-
dc.identifier.issn0022-2828-
dc.identifier.urihttp://hdl.handle.net/10722/202385-
dc.descriptionabstract no. P-2-18-6-
dc.description.abstractAbacavir is an antiviral nucleoside analogue effectively used to treat HIV infection. However, a study showed that the use of abacavir significantly increased the risks of stroke and myocardial infraction. We sought to investigate the effects of abacavir on vascular and platelet activities so as to understand the underlying mechanisms. Sprague-Dawley rats (330-350 g) were fed with abacavir (16 mg/kg/day, equivalent to the clinical dosage on human) for 28 days by gastric gavage. Isometric tensions of basilar arteries were measured. Aorta mRNA and proteins expressions of various factors related to endothelial function and inflammation were measured by RT-PCR and Western blotting, respectively. To measure the effect of abacavir on platelet activation, the plasma levels of CD40L, a platelet-derived factor which is released upon platelet activation, were measured by ELISA kit. Our results showed that abacavir treatment did not affect the maximum relaxation response of basilar artery. Besides, there were no significant change in the mRNA and protein expression levels of eNOS, COX-1, COX-2 and ICAM-1 in aorta after abacavir treatment. However, a higher plasma level of CD40L was detected in the abacavir-treated group. It is suggested that abacavir does not affect vascular contractility nor induced endothelial inflammation. However, abacavir upregulates the platelet activity, which will theoretically increase the chance of developing thrombosis. This may be a possible explanation for the higher risk of cardiovascular events in patients receiving abacavir treatment.-
dc.languageeng-
dc.publisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/yjmcc-
dc.relation.ispartofJournal of Molecular and Cellular Cardiology-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titleEffects of abacavir on the vascular and platelet activitiesen_US
dc.typeConference_Paperen_US
dc.identifier.emailLi, RWS: lirws@hku.hk-
dc.identifier.emailKwan, SYW: h1094107@hku.hk-
dc.identifier.emailLeung, GPH: gphleung@hku.hk-
dc.description.naturepostprint-
dc.identifier.doi10.1016/j.yjmcc.2010.03.009-
dc.identifier.hkuros170531-
dc.identifier.volume48-
dc.identifier.issue5 Suppl. 1-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats